Local recurrence of hepatocellular carcinoma after radiofrequency ablation

Aggressive tumor recurrence after radiofrequency ablation for hepatocellular carcinoma

Image-guided radiofrequency ablation (RFA) is an evolving and growing treatment option for patients with hepatocellular carcinoma (HCC) and hepatic metastasis. RFA offers significant advantages as it is less invasive than surgery and carries a low risk of major complications. However, serious complications, including aggressive tumor recurrence, may be observed during follow-up, and recently, m...

Radiofrequency Ablation of Hepatocellular Carcinoma

Radiofrequency Ablation for the Local Treatment of Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is the 3 leading cause of cancer-related death worldwide, and the incidence of HCC is rising in the United States. Patients with cirrhosis of the liver and viral hepatitis are at the highest risk of developing HCC. Radiofrequency ablation has become an accepted first-line treatment for small HCC because of its similar outcomes when compared with surgical resection...

Use of transient elastography to predict de novo recurrence after radiofrequency ablation for hepatocellular carcinoma

BACKGROUND/PURPOSE Liver stiffness (LS) measurement using transient elastography can accurately assess the degree of liver fibrosis, which is associated with the risk of the development of hepatocellular carcinoma (HCC). We investigated whether LS values could predict HCC de novo recurrence after radiofrequency ablation (RFA). METHODS This retrospective, multicenter study analyzed 111 patient...

Local recurrence and complications after percutaneous radiofrequency ablation of hepatocellular carcinoma: a retrospective cohort study focused on tumor location.

We conducted a retrospective cohort study to investigate the predisposing factors for local recurrence and complications after percutaneous radiofrequency ablation (RFA) of hepatocellular carcinoma (HCC). HCC patients (n＝397) consecutively treated with RFA (256 males, 141 females, median age 69 years) were enrolled. In these patients, 1,455 nodules (median size 17mm) were ablated. Predisposing ...